Tjoapack wins packaging contract for bladder cancer detection products
Tjoapack to perform the secondary packaging and assembly of product kits for supply to 25 European countries, the US, Canada and Australia.
Global contract packaging organisation, Tjoapack, has signed a 5-year agreement with Photocure for the packaging of its proprietary bladder cancer detection products.
Hexvix/Cysview is a drug that is selectively taken up by cancer cells in the bladder making them glow bright pink during Blue Light Cystoscopy (BLCTM). BLCTM with Hexvix/Cysview improves the detection of tumours and leads to more complete resection, less residual tumours and better management decisions.
The contract will see Tjoapack perform the secondary packaging and assembly of product kits for supply to 25 European countries, the US, Canada and Australia.
Dexter Tjoa, Director Corporate Strategy at Tjoapack said: “We’re delighted to be working with a company like Photocure whose technology can make such a difference to patients.
“Photocure has a global customer base, which comes with many potential challenges. At Tjoapack, we have a huge amount of experience in meeting the demands of multiple markets, especially when it comes to complying with legislation, such as artwork requirements and serialisation.
“In addition, the flexibility offered by our on-site warehousing facility will allow us to ensure continued supply in the shortest possible lead times. We hope this will be the start of a long and successful partnership.”
During the project, Tjoapack will be working with semi-finished stock stored at its facility, only finalising and assembling kits when orders come in.
Gry Stensrud, VP of Technical Development & Operations, at Photocure said: “Photocure delivers transformative solutions to improve the lives of bladder cancer patients. This is very much in line with Tjoapack’s ethos which was a big decision-making factor for us when choosing a partner.
“We were also specifically looking for a supplier who was ready for serialisation. While our product does not need to be serialised in the US as imaging drugs are exempt there, compliance with the EU FMD is vital to ensure continuous supply to our European markets.
“We were impressed by Tjoapack’s expertise in this area and are confident they’ll be able to meet our requirements.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.